La cadena de opciones muestra datos clave de las opciones de acciones de ZyVersa Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para ZyVersa Therapeutics..

ZyVersa Therapeutics (NASDAQ:ZVSA) Bolsa, Cadena de Opciones

ZyVersa Therapeutics

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics Inc

LXP Industrial Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXP#NYSE">LXP</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.15 by 6.67 percent. This is a 5.88 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $100.851 million which beat the analyst consensus estimate of $83.837 million by 20.29 percent. This is a 21.57 percent increase over sales of $82.956 million the same period last year.

Earnings

Earnings Beats

News

LXP Industrial Trust Q4 2024 FFO $0.16 Beats $0.15 Estimate, Sales $100.851M Beat $83.837M Estimate

<ul>
<li>Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC, in MTAP-deletion NSCLC</li>
<li>The potential first-in-class clinical combination of IDE397 and Trodelvy targets two mechanistically distinct and complementary nodes of MTAP-deletion in solid tumors</li>
<li>MTAP-deletion prevalence in NSCLC is estimated to be approximately 15%</li>
</ul>

Biotech

Health Care

Contracts

General

GILD

IDYA

IDEAYA Biosciences Announced An Additional Clinical Study Collaboration And Supply Agreement With Gilead Sciences To Evaluate IDE397 In Combination With Gilead's Trodelvy (Sacituzumab Govitecan) For Methylthioadenosine Phosphorylase-Deletion Non-Small Cell Lung Cancer

Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) reported quarterly losses of $(0.25) per share. This is a 108.33 percent decrease over losses of $(0.12) per share from the same period last year. The company reported $73.007 million in sales this quarter. This is a 20.24 percent decrease over sales of $91.530 million the same period last year.

Gogoro Q4 2024 GAAP EPS $(0.25) Down From $(0.12) YoY, Sales $73.007M Down From $91.530M YoY

Guidance

West Pharmaceutical Services Sees FY25 Adj. EPS $6.00-$6.20 vs. $7.44 Est., Revenue $2.875B-$2.905B vs. $3.042B Est.

YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>) reported quarterly earnings of $1.00 per share which beat the analyst consensus estimate of $0.93 by 7.53 percent. This is a 11.11 percent increase over earnings of $0.90 per share from the same period last year. The company reported quarterly sales of $546.54 million which missed the analyst consensus estimate of $551.97 million by 0.98 percent. This is a 5.15 percent increase over sales of $519.79 million the same period last year.

Earnings Misses

YETI

YETI Holdings Q4 2024 Adj EPS $1.00 Beats $0.93 Estimate, Sales $546.54M Miss $551.97M Estimate

Genesis Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEL#NYSE">GEL</a>) reported quarterly losses of $(0.58) per share. This is a 625 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $725.553 million in sales this quarter. This is a 6.27 percent decrease over sales of $774.104 million the same period last year.

Genesis Energy Q4 2024 GAAP EPS $(0.58) Down From $(0.08) YoY, Sales $725.553M Down From $774.104M YoY

Walker &amp; Dunlop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.22 by 9.84 percent. This is a 5.63 percent decrease over earnings of $1.42 per share from the same period last year. The company reported quarterly sales of $341.45 million which beat the analyst consensus estimate of $311.66 million by 9.56 percent. This is a 24.46 percent increase over sales of $274.34 million the same period last year.

Walker & Dunlop Q4 2024 Adj EPS $1.34 Beats $1.22 Estimate, Sales $341.45M Beat $311.66M Estimate

West Pharmaceutical Servs Q4 2024 Adj. EPS $1.82 Beats $1.72 Estimate, Sales $748.800M Beat $740.471M Estimate

Barclays analyst Duffy Fischer upgrades DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) from Underweight to Equal-Weight and raises the price target from $85 to $89.

Upgrades

Price Target

Analyst Ratings

Barclays Upgrades DuPont de Nemours to Equal-Weight, Raises Price Target to $89

Unilever Says Ice Cream Separation On Track; Ice Cream Will Be Separated By Way Of Demerger, Through Listing Of Business In Amsterdam, London And New YorK

The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) is the world's largest and arguably the most popular exchange-traded fund, with a whopping $630 billion in assets under management.
What happened: Launched in Jan. 1993, the SPY was also the first ETF to list on U.S.-based exchanges. It tracks the performance of the widely popular S&amp;P 500 Index, holding a portfolio comprising all 500 companies in the index.
Naturally, over such a long period, the ETF shares have gained tremendously, up roughly 1,273.15% since the launch.
However, the debut year wasn&#8217;t as exciting. In a year from its launch, the ETF grew from $43.61 to $47.38, representing an increase of 8.6%.
Initial interest in the ETF was poor, and the <a href="https://in.benzinga.com/25/01/43142623/happy-birthday-sp-500-spy-etf-if-you-invested-1000-in-spy-at-launch-heres-how-much-youd-have-today">fund was almost closed</a> before investors started welcoming the idea of using ETFs as investment vehicles.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43682382/robinhood-ceo-vlad-tenev-reveals-what-hes-most-excited-about-as-crypto-revenue-skyrockets-8x-stock-surges-15-after-hours">Robinhood CEO Vlad Tenev Reveals What He&#8217;s &#8216;Most Excited&#8217; About As Crypto Revenue Skyrockets 8X, Stock Surges 15% After Hours</a>
In contrast, BlackRock's iShares Bitcoin Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>), the world's largest cryptocurrency-based fund, smashed industry records in its debut year.
The investment vehicle, which exposes investors to the price of the world's biggest cryptocurrency Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), <a href="https://www.benzinga.com/24/12/42737368/blackrocks-bitcoin-fund-breaks-records-with-historic-etf-launchwill-it-surpass-the-worlds-biggest-gold-etf-in-january">amassed a record $50 billion in assets under management</a> within the first year.&nbsp;
Additionally, IBIT shares rose nearly 115% in the debut year, making it one of the most successful launches in ETF history.
IBIT has $55 billion in assets under management as of this writing. Though still far behind SPY&#8217;s achievements, leading ETF expert Eric Balchunas believed that <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42666635/blackrocks-bitcoin-etf-could-outshine-sp-500-tracking-spy-to-become-top-investment-vehicle-but-it-will-take-a-long-time-says-prominent-analyst">IBIT could outperform the King ETF</a> in the years to come, but the process would take a "long time."
Price Action: Shares of Robinhood soared 15.3% in after-hours trading, after closing 4.82% higher at $55.91 during Wednesday's trading session, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. 
Photo via Shutterstock
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43674050/us-releases-russian-bitcoin-exchange-co-founder-alexander-vinnik-in-prisoner-deal-with-moscow">US Releases Russian Bitcoin Exchange Co-Founder Alexander Vinnik In Prisoner Deal With Moscow</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

ETFs

$BTC

IBIT

S&P 500-Tracking SPY Boasts Of An Impressive Legacy, But Its Debut Pales In Comparison With BlackRock's Bitcoin Spot ETF

Suntory Beverage &amp; Food (OTC:<a class="ticker" href="https://www.benzinga.com/stock/STBFY#OTC">STBFY</a>) reported quarterly earnings of $0.11 per share. This is a 35.29 percent decrease over earnings of $0.17 per share from the same period last year. The company reported $2.75 billion in sales this quarter. This is a 2.08 percent increase over sales of $2.70 billion the same period last year.

STBFY

Suntory Beverage & Food Q4 EPS $0.11 Down From $0.17 YoY, Sales $2.75B Up From $2.70B YoY

Suntory Beverage &amp; Food (OTC:<a class="ticker" href="https://www.benzinga.com/stock/STBFY#OTC">STBFY</a>) is looking for FY2025 GAAP EPS JPY 291.26 vs JPY172.82 Est; Sees Sales JPY 1.796B

Suntory Beverage & Food Sees FY2025 GAAP EPS JPY 291.26 vs JPY172.82 Est; Sees Sales JPY 1.796B

Unilever Reports 2024 Underlying Sales Growth Of 4.2%, Led By 2.9% Volume Growth

Leerink Partners analyst Michael Cherny upgrades CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) from Market Perform to Outperform and raises the price target from $55 to $75.

Leerink Partners Upgrades CVS Health to Outperform, Raises Price Target to $75

Piper Sandler analyst Charles Neivert downgrades Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) from Overweight to Neutral and lowers the price target from $41 to $33.

Downgrades

Piper Sandler Downgrades Olin to Neutral, Lowers Price Target to $33

JP Morgan analyst Rodolfo Angele upgrades Ecopetrol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) from Underweight to Neutral and raises the price target from $7.5 to $9.5.

JP Morgan Upgrades Ecopetrol to Neutral, Raises Price Target to $9.5

U.S. stock futures were mixed on Thursday after a hotter-than-expected January inflation print, which was released on Wednesday.
The S&amp;P 500 and Dow Jones declined in premarket, whereas Nasdaq 100 and Russell 2000 were up.
Traders await the headline and core producer price index data for January which will be released before the market opens.
The 10-year Treasury yield stood at 4.61%, while the two-year yield was at 4.34%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool,</a> there is a 97.5% chance that the Federal Reserve will keep interest rates unchanged for the March meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.11%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.03%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.01%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.30%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) were mixed in premarket trading on Thursday. SPY fell 0.013% to $603.28, and QQQ was up 0.15% to $529.07, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
U.S. stocks mostly declined on Wednesday after January&#8217;s CPI exceeded expectations at 3% year-over-year and 0.5% monthly, which was the fastest pace of growth since August.
Materials, energy, and real estate sectors led losses, while consumer staples and communication services advanced.
Megacap tech like Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) fell, while Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rebounded over 2% after a five-day losing streak. CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) surged 15% on strong earnings.
The Dow fell 225 points or 0.50% to 44,368.56, the S&amp;P 500 was down 0.27% and closed at 6,051.97, and the Nasdaq Composite was above the flatline by 0.031% at 19,649.95. Russell 2000 Index fell 0.87% to 2,255.89.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.031%</td>
<td>19,649.95</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.27%</td>
<td>6,051.97</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.50%</td>
<td>44,368.56</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.87%</td>
<td>2,255.89</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
As President Donald Trump&#8216;s policies begin to take shape, Louis Navellier of Navellier &amp; Associates said that investors should not expect immediate action from the Federal Reserve, as the central bank is likely to remain on the sidelines until there is more clarity on which proposals will be enacted.
However, he said that despite the uncertainty surrounding Trump's new agenda, earnings remain strong, and consumer spending continues, suggesting positive momentum, though tempered with caution. As the details of the administration&#8217;s plans unfold, both the market and the Fed are likely to remain in a wait-and-see mode.
Ed Yardeni and Eric Wallerstein from Yardeni Research highlighted that the policy side effects of Trump 2.0 go beyond just Fed-related economic data, such as inflation and labor market reports. They pointed out that President Trump's announcement that Russia had agreed to start negotiations &#8220;immediately&#8221; to end the war in Ukraine provided a boost to stocks.
Talking about Wednesday&#8217;s CPI print, Subho Moulik, Founder &amp; CEO, Appreciate said that higher inflation could prompt policymakers in Washington to maintain a higher-for-longer stance—as seen in December 2024 when a marginal CPI beat reinforced the Fed's cautious approach.
&#8220;This hawkish tilt could push U.S. bond yields higher, strengthen the dollar, and trigger further capital outflows from emerging markets,&#8221; he added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Thursday:
<ul>
<li>Initial jobless claims till Feb. 8 will be out at 8:30 a.m., ET.</li>
<li>The headline and core producer price index data for January will be released at 8:30 a.m., ET as well.</li>
</ul>
Stocks In Focus:
<ul>
<li>Deere &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) was down 0.32% in premarket on Thursday ahead of its earnings, which will be released before the opening bell. Analysts expect it to report quarterly earnings of $3.11 per share on revenue of $7.70 billion.</li>
<li>GE Healthcare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) rose 0.13% as Wall Street expects it to report quarterly earnings of $1.26 per share on revenue of $5.33 billion before the opening bell.</li>
<li>Zebra Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) declined 0.26% ahead of its earnings, which will be released before the opening bell. Analysts expect it to report quarterly earnings of $3.94 per share on revenue of $1.32 billion.</li>
<li>Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) advanced 3.31% ahead of its earnings, which will be released after the closing bell. Analysts expect it to report quarterly earnings of $1.81 per share on revenue of $1.83 billion.</li>
<li>Applied Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) was down 0.1% as Wall Street expects it to report quarterly earnings of $2.29 per share on revenue of $7.14 billion after the closing bell.</li>
<li>Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) was up 5.97% after it reported better-than-expected second-quarter earnings and revealed an AI order pipeline of $700 million for the six months ended Jan. 25.</li>
<li>Fastly Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) dropped 20.26% after it reported a fourth-quarter loss of 3 cents per share. Whereas, the quarterly revenue came in at $140.58 million, beating the $138.27 million analyst consensus estimate.</li>
<li>HubSpot Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) was higher by 5.74% after it reported stronger-than-expected results for its fourth quarter.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 1.42% to hover around $70.36 per barrel.
The gold spot index was up by 0.43% to $2,916.84 per ounce. The Dollar Index was down 0.3% at 107.615 level.
Asian markets were mixed on Thursday as India's S&amp;P BSE Sensex, Hong Kong's Hang Seng, and China's CSI 300 index declined. Australia's ASX 200, South Korea's Kospi, and Japan's Nikkei 225 index advanced. European markets were mostly higher in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43684201/cvs-health-forecasts-10-earnings-growth-for-2025-citing-aetnas-meaningful-recovery">CVS Health Forecasts 10% Earnings Growth For 2025, Citing Aetna&#8217;s &#8216;Meaningful Recovery&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Macro Notification

Market Summary

Futures

Treasuries

Economics

Federal Reserve

Pre-Market Outlook

Trading Ideas

AMAT

AMZN

COIN

CSCO

FSLY

GEHC

GOOG

GOOGL

HUBS

TSLA

ZBRA

US Stocks Set For A Mixed Start Following Higher Inflation Print: Expert Says Earnings Remain Strong Despite Uncertainty

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is trading 2.2% higher in pre-market on Thursday following upbeat analyst calls on the stock as well as news over new EV taxes to finance road repairs which could impact its rivals.
What Happened: Today, Wedbush Securities analyst Dan Ives <a href="https://www.benzinga.com/25/02/43682491/elon-musks-doge-dedication-sparks-tesla-brand-deterioration-as-ev-maker-drops-20-after-trump-inauguration-dan-ives-says-bark-way-worse-than-the-bite">maintained his bullish stance</a> on Tesla and his $550 price target on the stock, despite concerns over Musk&#8217;s dedication to DOGE, causing potential brand deterioration.
Similarly, on Wednesday, Analyst Mickey Legg from Benchmark Equity placed a &#8216;Buy&#8217; rating and a $475 price target on the stock. He identified major growth drivers for Tesla in the fields of <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43675344/tesla-jumps-as-analyst-highlights-growth-in-evs-ai-robotics">autonomous vehicles, robotics, and energy generation </a>and storage. 
In another development, the U.S. Senate Republicans, on Wednesday, proposed two bills to remove the country&#8217;s $7,500 electric vehicle tax credit and introduce a new $1,000 tax on EVs to support road maintenance. This is likely to come as a blow to Tesla rivals like General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) who have been <a href="https://www.benzinga.com/markets/25/02/43648415/tesla-rivals-call-for-gradual-elimination-of-ev-tax-credits-many-of-those-jobs-will-be-at-risk">pushing for a gradual phase out </a>of the EV tax credits. Tesla has always maintained its stance on the elimination of EV subsidies.
SEE ALSO: <a href="https://www.benzinga.com/25/02/43681521/cathie-wood-dumps-more-palantir-amid-stocks-red-hot-rally-robinhood-also-gets-the-chop-ark-adds-amd-and-tsmc-stock">Cathie Wood Dumps More Palantir Amid Stock&#8217;s Red-Hot Rally, Robinhood Also Gets The Chop — Ark Adds AMD And TSMC Stock</a>
Why It Matters: Tesla&#8217;s growth prospects have been a topic of discussion, especially with CEO Elon Musk&#8217;s involvement in various ventures. 
Despite regulatory uncertainty and increasing EV competition putting downward pressure on vehicle pricing, analyst Mickey Legg is confident that Tesla&#8217;s product range will help mitigate these challenges. With $36.5 billion in cash and investments, the Elon Musk-led company is well-placed to pursue significant expansion possibilities, as per Legg. 
These events highlight the dynamic nature of Tesla&#8217;s operations and the potential impact of external factors on its growth trajectory.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/25/02/43686104/mitch-mcconnell-criticizes-trumps-tariff-plans-warns-of-potential-price-hike-big-lingering-concerns-for-american-industry-and-workers">Mitch McConnell Criticizes Trump&#8217;s Tariff Plans, Warns Of Potential Price Hike: &#8216;Big, Lingering Concerns For American Industry And Workers&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

Tesla Stock Climbs Over 2% In Thursday Pre-Market: What's Going On?

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Buy and lowers the price target from $94 to $84.

CRSP

Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $84

Warning: ZVSA is at high risk of performing badly

ZyVersa Therapeutics (ZVSA) highlights data from a review article published in the peer-reviewed journal, Life. The article summarizes data from 34...

ZyVersa highlights review article on inflammasome-induced inflammation

An announcement from ZyVersa Therapeutics ( ($ZVSA) ) is now available. ZyVersa Therapeutics' recent annual meeting saw key shareholder approvals, ...

ZyVersa Therapeutics' Shareholder Approvals and Director Elections

Bionomics, Simpple Ltd., and ZyVersa Therapeutics are the 3 Penny Stocks to watch on November 7, 2024, based on&nbsp;TipRanks' Penny Stock Screener...

3 Penny Stocks to Watch Now, 11/7/24

ZyVersa Therapeutics GAAP EPS of -$2.43 misses by $0.83

Zyversa Therapeutics, Inc. ( ($ZVSA) ) has released its Q3 earnings. Here is a breakdown of the information Zyversa Therapeutics, Inc. presented to...

ZyVersa Therapeutics Reports Q3 Progress and Outlook

ZyVersa Therapeutics (ZVSA) announces newly published data demonstrating that stroke-related cardiovascular injury and dysfunction is induced by AI...

ZyVersa Therapeutics announces publication on ASC Inhibitor IC 100

17:08 EST ZyVersa Therapeutics (ZVSA) files to sell 1.64M shares of common stock for holders Published first on TheFly – the ultimate source for re...

ZyVersa Therapeutics files to sell 1.64M shares of common stock for holders

BNOX

SPPL

ZVSA

Screenshot 2024-03-29 at 1.05.42 AM

CEO Of This Leading Biotech Speaks To The Critical Nature Inflammation Plays In The Body

Press Releases

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

"Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge"

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

Comments

ZyVersa Therapeutics

ZyVersa Therapeutics (ZVSA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL